Double or triple down: how AFT Pharmaceuticals plans to win in China

Double or triple down: how AFT Pharmaceuticals plans to win in China
(Image: Getty)
Rebecca Stevenson
AFT Pharmaceuticals says it has increased manufacturing capacity and brought in market experts as it prepares to launch its antibacterial cream in China. The New Zealand Exchange-listed (NZX) firm reported its results for the 12 months to March 31 on May 23. Its international and Asian sales rose 70%, accounting for 20% of revenue. Operating revenue for AFT’s Asian business grew 57% to $10.7 million from $6.8m, while operating profit rose to $2.5m from $900,000.It said growth was driven through the hospital channel, wi...

More Markets

Rakon stock-price climb triggers watchdog review
Markets

Rakon stock-price climb triggers watchdog review

Rakon shares rose almost 9% on Wednesday but spiked even higher during the day.

Fisher Funds backs Summerset in rejecting covenant waiver claims
Markets

Fisher Funds backs Summerset in rejecting covenant waiver claims

Summerset is compliant with all lending covenants and obligations.

Critical minerals miner plans 2026 NZX listing
Primary Sector

Critical minerals miner plans 2026 NZX listing

The company plans to raise $20m from retail investors in mid-2026.

Genesis backs Huntly longevity as renewables pipeline expands
Markets

Genesis backs Huntly longevity as renewables pipeline expands

Huntly is cash-positive in every scenario to FY35 as Genesis expands renewables.